Call Celebration of Health Association at 800-788-4627.
Thursday, January 8, 2015
The Trial to Assess Chelation Therapy, Phase 2The Trial to Assess Chelation Therapy, Phase 2The Trial to Assess Chelation Therapy, Phase 2The Trial to Assess Chelation Therapy, Phase 2The Trial to Assess Chelation Therapy, Phase 2
TACT-1 was
a huge study that showed that chelation therapy can prevent future cardiac
events for patients who had suffered a previous heart attack. Chief Investigator, Dr. Gervasio Lamas, has
published the study in major journals and presented the data at many medical
schools across the U.S. The most
impressive part of the study was a 51% reduction in cardiac events in diabetic
patients over a 5-year period. The FDA
was impressed as well, but they demand a confirmatory study for acceptance of
chelation therapy. Thus we now have
TACT-2. If you know anyone who is a
diabetic and has had at least one heart attack, please have him or her contact
our office to find out if they are eligible to participate in the study. They would have a 2/3 probability of receiving
$10,000 worth of treatment, without cost.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment